Your search history is turned on.
Date: April 24, 2024 Jurisdictions: All jurisdictions
BriaCell Announces Oral and Poster Presentations at ASCO 2024 Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MD Two poster presentations include Drs. Hurvitz (Fred Hutchinson Cancer Center), Brufsky (UPMC), and Cristofanilli (Weill Cornell) as authors PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2024 -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX...
Date: April 10, 2024 Jurisdictions: All jurisdictions
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+ and Bria-PROS+ Clinical Candidates for Breast and Prostate Cancer Preclinical data shows that BriaCells Bria-OTS+ and Bria-PROS+ effectively induce an anti-cancer immune response via multiple mechanisms including nave helper and killer T cells, dendritic cells, and natural killer (NK) cells The novel mechani...
Date: April 9, 2024 Jurisdictions: All jurisdictions
BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT pivotal Phase 3 formulation is twice that of controls in similar studies PFS results reinforced by larger numb...
Date: March 18, 2024 Jurisdictions: All jurisdictions
Submission Proof - Z:\2024 OPERATIONS\EDGAR\02 FEBRUARY\BRIACELL THERAPEUTICS CORP\02-22-2024\Form10-Q (January 31, 2024)\Draft Exhibit 31.2 CERTIFICATION I, Gadi Levin, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of BriaCell Therapeutics Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material f...
Submission Proof - Z:\2024 OPERATIONS\EDGAR\02 FEBRUARY\BRIACELL THERAPEUTICS CORP\02-22-2024\Form10-Q (January 31, 2024)\Draft Exhibit 31.1 CERTIFICATION I, William V. Williams, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of BriaCell Therapeutics Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a m...
file:///Z:/2024%20OPERATIONS/EDGAR/02%20FEBRUARY/BRIACELL%20THE Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations. References to the Company, our, us or we refer to BriaCell Therapeutics Corp. The following discussion and analysis of the Companys financial condition and results of operations should be read in conju...
Proof - form10-q.htm PART I-FINANCIAL INFORMATION Item 1. Financial Statements BRIACELL THERAPEUTICS CORP. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS January 31, 2024 July 31, 2023 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 6,244,528 $ 21,251,092 Amounts receivable 30,145 18,873 Prepaid expenses 5,467,286 5,678,542 Total current assets 11,7...
Date: March 7, 2024 Jurisdictions: All jurisdictions
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCells novel off-the-shelf personalized cancer vaccines, marks a major milestone for BriaCell PHILADELPHIA and VANCOUVER, British Co...
Date: March 6, 2024 Jurisdictions: All jurisdictions
BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference PHILADELPHIA and VANCOUVER, British Columbia, March 06, 2024 -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (BriaCell or the Company), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer...
Date: February 27, 2024 Jurisdictions: All jurisdictions
BriaCell Provides Update on Alleged Illegal Trading of Public Securities PHILADELPHIA and VANCOUVER, British Columbia, Feb. 27, 2024 -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (BriaCell or the Company), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, provides an update to the previously announced investigation of alleged illegal trading ...